http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-510572-A

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-401
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
filingDate 1996-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32a6dc4fb412c3e729924d6872e03ae2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4eccd2861cf0715a4c6ce7c516de1ca
publicationDate 2002-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NZ-510572-A
titleOfInvention Use of a combination of angiotensin converting enzyme inhibitor, aldosterone antagonist and diuretic for treating cardiovascular diseases
abstract An angiotensin converting enzyme inhibitor a, a diuretic agent and an aldosterone receptor antagonist are used to treat cardiovascular diseases in a subject afflicted with or susceptible to multiple cardiovascular disorders. The amount of aldosterone receptor antagonist present is therapeutically effective to antagonize aldosterone but insufficient to induce an adverse side effect and to provide a daily dosage range of 5-22.5 mg per dose.
priorityDate 1995-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP31351
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP30426
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP08318
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCC9X4J0
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP30424
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419481582
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5839
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP86643
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP85165
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP0DQU4

Total number of triples: 38.